CDMO Blog

Concentration and Reformulation of Cellular Immunotherapies – A Major Downstream Processing Step

An-image-of-the-GE-Sefia-Cell-Processing-SystemCellular immunotherapies (e.g. CAR-T cells) are primarily used as an autologous therapy to treat cancer. As such, these therapies are currently generated in small batches for each patient. To generate enough modified cells for a single treatment, cells are expanded in volumes from 1-10 L. In the final step of downstream processing (DSP) for immunotherapies, cells cultured in large volumes must be concentrated and reformulated into smaller volumes (e.g. 20-100 mL) suitable for delivery to patients.

Read More
Posted: Oct 30, 2019 3:48:28 PM

How Can a Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs and Improve Efficiency?

Instrument enabling Car-T process development

In a previous post we introduced chimeric antigen receptor T-cell (CAR-T) therapy - a new form of cancer therapy based on genetically reprogramming the body’s immune system that has been described as a “breakthrough” and “revolutionary” by the medical and scientific communities.

Read More
Posted: Oct 24, 2019 3:22:49 PM